Evaluation in nonhuman primates of vaccines against Ebola virus

Thomas Geisbert, Peter Pushko, Kevin Anderson, Jonathan Smith, Kelly J. Davis, Peter B. Jahrling

Research output: Contribution to journalArticle

194 Citations (Scopus)

Abstract

Ebola virus (EBOV) causes acute hemorrhagic fever that is fatal in up to 90% of cases in both humans and nonhuman primates. No vaccines or treatments are available for human use. We evaluated the effects in nonhuman primates of vaccine strategies that had protected mice or guinea pigs from lethal EBOV infection. The following immunogens were used: RNA replicon particles derived from an attenuated strain of Venezuelan equine encephalitis virus (VEEV) expressing EBOV glycoprotein and nucleoprotein; recombinant Vaccinia virus expressing EBOV glycoprotein; liposomes containing lipid A and inactivated EBOV; and a concentrated, inactivated whole-virion preparation. None of these strategies successfully protected nonhuman primates from robust challenge with EBOV. The disease observed in primates differed from that in rodents, suggesting that rodent models of EBOV may not predict the efficacy of candidate vaccines in primates and that protection of primates may require different mechanisms.

Original languageEnglish (US)
Pages (from-to)503-507
Number of pages5
JournalEmerging Infectious Diseases
Volume8
Issue number5
StatePublished - 2002
Externally publishedYes

Fingerprint

Ebola Vaccines
Ebolavirus
Primates
Vaccines
Rodentia
Glycoproteins
Ebola Hemorrhagic Fever
Venezuelan Equine Encephalitis Viruses
Lipid A
Replicon
Nucleoproteins
Vaccinia virus
Liposomes
Virion
Guinea Pigs
Fever
RNA

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

Geisbert, T., Pushko, P., Anderson, K., Smith, J., Davis, K. J., & Jahrling, P. B. (2002). Evaluation in nonhuman primates of vaccines against Ebola virus. Emerging Infectious Diseases, 8(5), 503-507.

Evaluation in nonhuman primates of vaccines against Ebola virus. / Geisbert, Thomas; Pushko, Peter; Anderson, Kevin; Smith, Jonathan; Davis, Kelly J.; Jahrling, Peter B.

In: Emerging Infectious Diseases, Vol. 8, No. 5, 2002, p. 503-507.

Research output: Contribution to journalArticle

Geisbert, T, Pushko, P, Anderson, K, Smith, J, Davis, KJ & Jahrling, PB 2002, 'Evaluation in nonhuman primates of vaccines against Ebola virus', Emerging Infectious Diseases, vol. 8, no. 5, pp. 503-507.
Geisbert T, Pushko P, Anderson K, Smith J, Davis KJ, Jahrling PB. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerging Infectious Diseases. 2002;8(5):503-507.
Geisbert, Thomas ; Pushko, Peter ; Anderson, Kevin ; Smith, Jonathan ; Davis, Kelly J. ; Jahrling, Peter B. / Evaluation in nonhuman primates of vaccines against Ebola virus. In: Emerging Infectious Diseases. 2002 ; Vol. 8, No. 5. pp. 503-507.
@article{bf6d7f31e25d4c0abeea11c14cd22b2a,
title = "Evaluation in nonhuman primates of vaccines against Ebola virus",
abstract = "Ebola virus (EBOV) causes acute hemorrhagic fever that is fatal in up to 90{\%} of cases in both humans and nonhuman primates. No vaccines or treatments are available for human use. We evaluated the effects in nonhuman primates of vaccine strategies that had protected mice or guinea pigs from lethal EBOV infection. The following immunogens were used: RNA replicon particles derived from an attenuated strain of Venezuelan equine encephalitis virus (VEEV) expressing EBOV glycoprotein and nucleoprotein; recombinant Vaccinia virus expressing EBOV glycoprotein; liposomes containing lipid A and inactivated EBOV; and a concentrated, inactivated whole-virion preparation. None of these strategies successfully protected nonhuman primates from robust challenge with EBOV. The disease observed in primates differed from that in rodents, suggesting that rodent models of EBOV may not predict the efficacy of candidate vaccines in primates and that protection of primates may require different mechanisms.",
author = "Thomas Geisbert and Peter Pushko and Kevin Anderson and Jonathan Smith and Davis, {Kelly J.} and Jahrling, {Peter B.}",
year = "2002",
language = "English (US)",
volume = "8",
pages = "503--507",
journal = "Emerging Infectious Diseases",
issn = "1080-6040",
publisher = "Centers for Disease Control and Prevention (CDC)",
number = "5",

}

TY - JOUR

T1 - Evaluation in nonhuman primates of vaccines against Ebola virus

AU - Geisbert, Thomas

AU - Pushko, Peter

AU - Anderson, Kevin

AU - Smith, Jonathan

AU - Davis, Kelly J.

AU - Jahrling, Peter B.

PY - 2002

Y1 - 2002

N2 - Ebola virus (EBOV) causes acute hemorrhagic fever that is fatal in up to 90% of cases in both humans and nonhuman primates. No vaccines or treatments are available for human use. We evaluated the effects in nonhuman primates of vaccine strategies that had protected mice or guinea pigs from lethal EBOV infection. The following immunogens were used: RNA replicon particles derived from an attenuated strain of Venezuelan equine encephalitis virus (VEEV) expressing EBOV glycoprotein and nucleoprotein; recombinant Vaccinia virus expressing EBOV glycoprotein; liposomes containing lipid A and inactivated EBOV; and a concentrated, inactivated whole-virion preparation. None of these strategies successfully protected nonhuman primates from robust challenge with EBOV. The disease observed in primates differed from that in rodents, suggesting that rodent models of EBOV may not predict the efficacy of candidate vaccines in primates and that protection of primates may require different mechanisms.

AB - Ebola virus (EBOV) causes acute hemorrhagic fever that is fatal in up to 90% of cases in both humans and nonhuman primates. No vaccines or treatments are available for human use. We evaluated the effects in nonhuman primates of vaccine strategies that had protected mice or guinea pigs from lethal EBOV infection. The following immunogens were used: RNA replicon particles derived from an attenuated strain of Venezuelan equine encephalitis virus (VEEV) expressing EBOV glycoprotein and nucleoprotein; recombinant Vaccinia virus expressing EBOV glycoprotein; liposomes containing lipid A and inactivated EBOV; and a concentrated, inactivated whole-virion preparation. None of these strategies successfully protected nonhuman primates from robust challenge with EBOV. The disease observed in primates differed from that in rodents, suggesting that rodent models of EBOV may not predict the efficacy of candidate vaccines in primates and that protection of primates may require different mechanisms.

UR - http://www.scopus.com/inward/record.url?scp=0036094058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036094058&partnerID=8YFLogxK

M3 - Article

C2 - 11996686

AN - SCOPUS:0036094058

VL - 8

SP - 503

EP - 507

JO - Emerging Infectious Diseases

JF - Emerging Infectious Diseases

SN - 1080-6040

IS - 5

ER -